The association of COVID-19 with executive functioning raises key questions regarding patients' longterm treatment. Future studies are needed to identify the risk factors and mechanisms underlying cognitive dysfunction as well as options for rehabilitation.
Buprenorphine is considered one of the most effective treatments for
opioid use disorder and significantly reduces risk of overdose death. However,
concerns about its diversion and misuse have often taken center stage in public
discourse and in the design of practices and policies regarding its use. This
has been to the detriment of many vulnerable patient populations, especially
those involved in the criminal justice system. Policies that restrict access to
buprenorphine in criminal justice and other settings due to concerns of
diversion do not accurately reflect the relative risks and safety profile
associated with it, creating unnecessary barriers that drive an illicit market
of this much-needed medication. Although proper regulation of all controlled
medications should be a priority, in most instances the benefits of
buprenorphine highly outweigh its risks. In the midst of a national crisis,
efforts should be focused on expanding, and not restricting, access to this
life-saving treatment.
Possibly through its effects on glia, the peroxisome proliferator-activated gamma receptor (PPARγ) agonist pioglitazone (PIO) has been shown to alter the effects of heroin in preclinical models. Until now, these results have not been assessed in humans. Heroin-dependent participants were randomized to either active (45 mg, n = 14) or placebo (0 mg, n = 16) PIO maintenance for the duration of the three-week study. After stabilization on buprenorphine (8 mg), participants began a two-week testing period. On the first to fourth test days, participants could self-administer drug or money by making verbal choices for either option. On the fifth day, active heroin and money were administered and participants could work to receive heroin or money using a progressive ratio choice procedure. Test days 6-10 were identical to test days 1-5 with the exception that, during one of the test weeks, placebo was available on the first four days, and during the other week heroin was available. PIO failed to alter the reinforcing or positive subjective effects of heroin, but it did reduce heroin craving and overall anxiety. Although we were unable to replicate the robust effects found in preclinical models, these data provide an indication of drug effects that deserves further exploration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.